Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults.

Abstract

In this 13-week, open-label, randomized study of the anti-inflammatory salsalate versus usual care, there were no significant improvements in flow-mediated dilation of the brachial artery, endothelial activation, inflammation or coagulation markers, homeostasis model assessment of insulin resistance or lipoproteins with salsalate or between groups in virologically suppressed, HIV-infected adults on antiretrovirals. Tinnitus and transaminitis occurred frequently in the salsalate group. Dose reduction due to toxicities encountered and low level of inflammation may explain these results.

• Authors: Corrilynn O Hileman, Teresa L Carman, Barbara M Gripshover, Maryann O'Riordan, Norma J Storer, Danielle E Harrill, Cynthia A White, Grace A McComsey
• Journal: AIDS (London, England) (AIDS) Vol. 24 Issue 12 Pg. 1958-61 (Jul 31 2010) ISSN: 1473-5571 [Electronic] England
• PMID: 20613460 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Salicylates
• salicylsalicylic acid

Topics

• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects)
• Brachial Artery (physiopathology)
• Dose-Response Relationship, Drug
• Endothelium, Vascular (drug effects, physiopathology)
• Female
• HIV Infections (drug therapy, physiopathology)
• Humans
• Insulin Resistance
• Male
• Salicylates (administration & dosage, adverse effects)